Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SGMT
SellSagimet Biosciences Inc. · Healthcare · United States · $656M · Avg Vol: $12M/d
COMPANY DESCRIPTION
Sagimet Biosciences Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for metabolic diseases. The company's lead product candidate targets fatty acid synthase (FASN) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Sagimet operates in the highly competitive pharmaceutical industry, aiming to carve out a niche with its differentiated approach to fatty acid metabolism for liver disease and other conditions.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 2.0M | 0 | 0 | — | — | — | 7.8M | 40.6% |
| EPS | -0.50 | -1.00 | -1.45 | -1.58 | — | -1.33 | -1.20 | -1.38 | — |
| Shares | 61.2M | 61.2M | 32.2M | 32.5M | -46.8% | — | — | — | — |
| Debt | 0.2M | 65.0K | 78.0K | 78.0K | -28.2% | — | — | — | — |
| Equity | -186.9M | 91.1M | 155.8M | 111.4M | 10.6% | — | — | — | — |
| Op CF | -24.5M | -23.8M | -42.4M | -45.6M | — | -41.7M | — | — | — |
| Inv CF | -32.0M | 12.6M | -61.7M | 4.6M | — | — | — | — | — |
| Fin CF | -73.0K | 86.2M | 104.8M | 0.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SGMT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SGMT | Sagimet Biosciences Inc.(you) | $656M | 33 | Sell |
| CTNM | Contineum Therapeutics, Inc. | $641M | 35 | Sell |
| NGNE | Neurogene Inc. | $732M | 34 | Sell |
| TECX | Tectonic Therapeutic, Inc. | $696M | 35 | Hold |
| GYRE | Gyre Therapeutics, Inc. | $699M | 35 | Hold |
| CCCC | C4 Therapeutics, Inc. | $474M | 33 | Sell |
| DRUG.CN | Bright Minds Biosciences Inc. | $717M | 28 | Sell |
| CBIO | Crescent Biopharma, Inc. | $659M | 26 | Sell |
| DSGN | Design Therapeutics, Inc. | $946M | 33 | Sell |
| FTH | Faeth Therapeutics, Inc. | $874M | 31 | Sell |
Peer medians: ROE -25.0% · P/E 31.0x · Gross margin 58.8%